American International Group Inc vs Neurocrine Biosciences Inc — how do they compare? American International Group Inc trades at $77.4 (market cap $40.42B), while Neurocrine Biosciences Inc trades at $152.36 (market cap $16.46B). The key difference: American International Group Inc is far larger — about 2.5× Neurocrine Biosciences Inc's market cap, and American International Group Inc pays a 2.59% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| AIG | NBIX | |
|---|---|---|
Market Cap | $40.42B | $16.46B |
Sector | Financials | Health |
52-Week High | $86.59 | $185.50 |
52-Week Low | $71.89 | $123.10 |
Enterprise Value | $48.06B | $16.48B |
Dividend Yield | 2.59% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Neurocrine Biosciences (NBIX) trades at $163.41, up 2.25% today, with a bearish technical signal but strong fundamentals including a 39% revenue growth in Q2 2026 and a net income margin of 20.91%. Recent news highlights Phase 1 trial initiation for a GLP-1/GIP/glucagon receptor agonist and leadership appointments, supporting growth prospects.
The outlook is positive with an analyst consensus price target of $208.82, implying 28% upside, driven by robust earnings beats and pipeline advancements. Risks include clinical trial outcomes and competitive pressures in biopharma, but institutional buying and high analyst buy ratings (86.49%) reflect confidence in execution.
Trailing returns across standard periods
American International Group is one of the largest insurance and financial services firms in the world and has a global footprint. It operates through a wide range of subsidiaries that provide property, casualty, and life insurance. Its revenue is split roughly evenly between commercial and consumer lines.
Read more on AIG →Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →